Mar 28th, 2023 - Mutations continue to accumulate within the SARS-CoV-2 genome, and the ongoing epidemic has shown no signs of ending. It is critical to predict problematic mutations that may arise in clinical environments and assess their properties in advance to quickly implement countermeasures against future variant infections. In this study, we identified mutations resistant to remdesivir, which is widely ...

Mar 26th, 2023 - The identification of the SARS-CoV-2 Omicron variants BA.4/BA.5, BF.7 and BQ.1.1 immediately raised concerns regarding the efficacy of currently used monoclonal antibody therapies. Here we examined the activity of monoclonal antibody therapies and antiviral drugs against clinical specimens for SARS-CoV-2 Omicron BA.4/BA.5, BF.7 and BQ.1.1 employing an immunofluorescence neutralization assay. Fu...

Mar 25th, 2023 - Since the beginning of coronavirus disease 2019 (COVID-19), several therapies have been purposed. Remdesivir has emerged as an encouraging antiviral drug with for the treatment of severe patients with documented COVID-19-related pneumonia. Although several studies about remdesivir effectiveness exist, no study investigated the combination of remdesivir with the vaccination status. The aim of th...

Mar 23rd, 2023 - During the COVID-19 pandemic, efforts to maintain solid-organ transplantation have continued, including the use of SARS-CoV-2-positive heart donors. We present our institution's initial experience with SARS-CoV-2-positive heart donors. All donors met our institution's Transplant Center criteria, including a negative bronchoalveolar lavage polymerase chain reaction result. All but 1 patient rece...

Mar 22nd, 2023 - Purpose: Remdesivir use in COVID-19 is associated with cardiac conduction abnormalities from unclear mechanisms. A proposed mechanism is the bioaccumulation of the intermediate metabolite GS-441524 resulting in exogenous activation of cardiac adenosine A1 due to the structural similarity between adenosine and GS-441524. The prolonged half-life of GS-441524 can result in sustained activation of ...

Mar 19th, 2023 - VV116 is a chemically-modified version of the antiviral remdesivir with oral bioavailability and potent activity against SARS-CoV-2. The optimal treatment of standard-risk outpatients who develop mild-to-moderate COVID-19 is controversial. While several therapeutic are currently recommended, including nirmatrelvir-ritonavir (Paxlovid), molnupiravir, and remdesivir, these treatments have substan...

Mar 18th, 2023 - Observational studies have identified potential prognostic value for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) viral load and anti-SARS-CoV-2 antibodies in COVID-19. However, viral load in nasopharyngeal swabs produced inconsistent results in prognostic analyses, and the prognostic value of viral load or antibodies has not been confirmed in large clinical trials. COVACTA and ...

Mar 18th, 2023 - To evaluate the impact of local therapeutic recommendation updates made by the COVID multidisciplinary consultation meeting (RCP) at the Hôpital Européen Marseille (HEM) through the description of the drug prescriptions for COVID-19 during the first two waves of the epidemic. This retrospective observational study analysed data from the hospital's pharmaceutical file. We included all patients h...

Mar 17th, 2023 - Approach Considerations Utilization of programs established by the FDA to allow clinicians to gain access to investigational therapies during the pandemic has been essential. The expanded access (EA) and emergency use authorization (EUA) programs allowed for rapid deployment of potential therapies for investigation and investigational therapies with emerging evidence. A review by Rizk et al des...

Mar 16th, 2023 - SPL UNCLASSIFIED SECTION HIGHLIGHTS OF EMERGENCY USE AUTHORIZATION (EUA) These highlights of the EUA do not include all the information needed to use SOTROVIMAB under the EUA. See the FULL FACT SHEET FOR HEALTHCARE PROVIDERS for SOTROVIMAB. SOTROVIMAB injection, for intravenous use Original EUA Authorized Date: 05/2021 ---------------------------- RECENT MAJOR CHANGES --------------------------...

Mar 15th, 2023 - Nirmatrelvir-ritonavir (Paxlovid) wards off severe disease in high-risk COVID patients, but drug interactions at the individual level often disfavor its use, said FDA staff in briefing documents released ahead of an advisory committee meeting. On Thursday, the Antimicrobial Drugs Advisory Committee will weigh in on the strength of evidence for use of the oral antiviral in outpatients at risk fo...

Mar 14th, 2023 - To examine the impact of commonly used case definitions for coronavirus disease 2019 (COVID-19) hospitalizations on case counts and outcomes. Retrospective analysis of all adults hospitalized between March 1, 2020, and March 1, 2022, at 5 Massachusetts acute-care hospitals. We applied 6 commonly used definitions of COVID-19 hospitalization: positive severe acute respiratory coronavirus virus 2 ...

Mar 12th, 2023 - Recently, a benefit from administration of a 3-day course of early remdesivir (ER) in the outpatients' setting was reported. However, real-life data on its use is scarce. Therefore, we explored the ER clinical outcome in our outpatients' s cohort, compared to untreated controls. We included all patients who were prescribed ER from February to May 2022 and followed them up for three months and c...

Mar 12th, 2023 - The combined effectiveness of remdesivir and dexamethasone in subgroups of hospitalised patients with COVID-19 is poorly investigated. In this nationwide retrospective cohort study, we included 3826 patients with COVID-19 hospitalised between February 2020 and April 2021. The primary outcomes were use of invasive mechanical ventilation and 30-day mortality, comparing a cohort treated with remde...

Mar 10th, 2023 - Safety of Tocilizumab and Remdesivir in Treating COVID-19 Pneumonia in Premature Twins.|2023|Bihm D,Huang J,Yi B,Posch L,Brown D,|

Mar 10th, 2023 - Identification of host determinants of coronavirus infection informs mechanisms of viral pathogenesis and can provide new drug targets. Here we demonstrate that mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) chromatin remodeling complexes, specifically canonical BRG1/BRM-associated factor (cBAF) complexes, promote severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and r...

Mar 3rd, 2023 - Remdesivir, a viral RNA-dependent RNA polymerase inhibitor, found extensive use in coronavirus disease 2019-infected patients because it curbs the viral load expansion. Among patients hospitalized as a result of lower respiratory tract infection, remdesivir proved to improve recovery time; however, remdesivir also can induce significant cytotoxic effects on cardiac myocytes. In this narrative r...

Feb 28th, 2023 - Chronic kidney disease (CKD) is an important risk factor for mortality from COVID-19. Remdesivir has been shown to shorten time to recovery in patients with severe COVID-19. However, exclusion of patients with severe kidney function impairment in clinical trials has led to concerns about kidney safety of remdesivir in patients with pre-existing kidney disease. Retrospective propensity score mat...

Feb 28th, 2023 - Despite its contradictory clinical performance, Veklury® (remdesivir) has a pivotal role in COVID-19 therapy. Possible contributions of the vehicle sulfobutylether-β-cyclodextrin (SBECD) to Veklury® effects are neglected and the powder and solution formulations of Veklury® are treated equivalently despite their different vehicle content. Our objective was to study Veklury® effects on initial me...

Feb 28th, 2023 - We aimed to describe practice patterns and outcomes in patients with extracorporeal membrane oxygenation (ECMO) support throughout the coronavirus 2019 (COVID-19) pandemic, with the hypothesis that mortality would improve as we accumulated knowledge and experience. We included 48 patients supported on veno-venous ECMO (VV-ECMO) at a single institution between April 2020 and December 2021. Patie...